

DAFTAR PUSTAKA

- Abhay S. Inferring Molecular Mechanisms of Dexamethasone Therapy in Severe COVID-19 From Existing Transcriptomic Data. *Gene*. 2021: 788.
- Acat M, Çavdar Ö, Tezce A, Acat BP. Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience. *Duzce Medical J*. 2022; 24 (2): 116-20.
- Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. *Immunol Cell Biol*. 2001; 79(4) : 376–84.
- Ahmadian E, Hosseiniyan SM, Soofiyan RS, Abediazar S, Shoja MM, Ardalan M, et al. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. *Rev Med Virol*. 2021; 31(3) : 2176.
- Akter F, Araf Y, Hosen MJ. Corticosteroids for COVID-19: worth it or not?. *Mol Biol Rep*. 2022; 49(1): 567-76.
- AMillán IF, Salvatierra J, Parejo TÚ, Miguez FN, Rubio CJL, Torres CÁ, et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. *Intern Emerg Med*. 2021; 16(4): 843-52.
- Aon M, Alsaeedi A, Alzafiri A, Ibrahim MM, Al-Shammari A, Al-Shammari O., et al. The Association between Admission Procalcitonin Level and The Severity of COVID-19 Pneumonia: A Retrospective Cohort Study. *Medicina*. 2022; 58(10): 1389.
- Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. *Am. J. Respir. Crit. Care Med*. 2018; 197(6) : 757–67.
- ALaarhoven A, Kurver L, Overheul GJ. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series. *Med*. 2021; 2(10) : 1163–70.
- Atlas of Genetics and Cytogenetics in Oncology and Haematology. (2021). CXCR3 (chemokine (C-X-C motif) receptor 3). Available at: <http://atlasgeneticsoncology.org/Genes/CXCR3ID40224chXq13.html>.
- Awasthi S, Wagner T, Venkatakishnan AJ, Puranik A, Hurchik M, Agarwal V. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. *Cell Death Discov*. 2021; 7(1):55.
- Balkhair AA. COVID-19 Pandemic: A New Chapter in the History of Infectious Diseases. *Oman Medical Journal*. 2020; 35(2):123.
- Basu A, Agwu JC, Barlow N, Lee B. Hypertension is the major predictor of poor outcomes among inpatients with COVID-19 infection in the UK: a retrospective cohort study. *Brit Med J open*. 2021; 11(6): 047561.
- Batta Y, King C, Johnson J, Haddad N, Boueri M, Haddad G. Sequelae and Comorbidities of COVID-19 Manifestations on the Cardiac and the Vascular Systems. *Front Physiol*. 2022; 12:748972.

- Batur L, Hekim N. Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries. *J Med Virol*. 2021; 93(10), 5853–63.
- Bell LCK, Meydan C, Kim J, Foox J, Butler, D, Mason, et al. Transcriptional response modules characterize IL-1 β and IL-6 activity in COVID-19. *iScience*. 2021; 24(1).
- Berlot G, Passero S. Immunoparalysis in Septic Shock Patients. In (Ed.), *Infectious Process and Sepsis*. Intech Open. 2022.
- Betti M, Bertolotti M, Ferrante D, Roveta A, Pelazza C, Giacchero F, et al. Baseline clinical characteristics and prognostic factors in hospitalized COVID-19 patients aged ≤ 65 years: A retrospective observational study. *PLoS One*. 2021; 16(3).
- Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. *Front. Immunol*. 2020; 11 : 1648.
- Birhanu A, Merga BT, Ayana GM, Alemu A, Negash B, Dessie Y, et al. Factors associated with prolonged length of hospital stay among COVID-19 cases admitted to the largest treatment center in Eastern Ethiopia. *SAGE open medicine*. 2022; 10
- Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirol*. 2020: 1-12.
- Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?. 2014 *Virulence*, 5(1) : 45–56.
- Booth, V, Keizer DW, Kamphuis MB, Clark-Lewis I, Sykes BD. The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. *Biochemistry*. 2022; 41(33): 10418–25.
- Boraschi D, Tagliabue A. The interleukin-1 receptor family. *Semin Immunol*. 2013; 25(6): 394-407.
- Burhan E, Agus DS, Fathiyah I. Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). *Pedoman Tatalaksana COVID-19 Ed 3 Desember 2020*. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI. 2022 :149.
- Catalin C, Pasca S, Tat T, Teodorescu, Vlad CS. Iluta, et al. Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies? *J Immunother Cancer*. 2020; 8(1): 742.
- Cai R, Zhang J, Zhu Y, Liu L, Liu Y, He Q. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. *Int Urol Nephrol*: 2020: 1–7.

- Cheng W, Peng Y, Zhou A, Lin L, Liao X, Deng D, et al. Comparative clinical characteristics among different age group of adult COVID-19 patients: A multicenter study. *Immun Inflamm Dis*. 2022; 10(2):130–42.
- Chousterman BG, Swirski, FK and Weber GF. Cytokine storm and sepsis disease pathogenesis. *Semin Immunopathol*. 2017; 39(5): 517–28.
- Choy, E. and Rose-John, S. Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis. *Scleroderma Relat Disord*. 2017; 2(2): S1–S5.
- Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. *Cytokine Growth Factor Rev*. 2020; 53: 25–32.
- Costa IBS. O Coração e a COVID-19: O que o Cardiologista Precisa Saber?, *Arquivos Brasileiros de Cardiologia*. 2020; 114(5) : 805–16.
- Cremoni M, Allouche J, Graça D, Zorzi K, Fernandez C, Teisseyre M, et al. Low baseline IFN- γ response could predict hospitalization in COVID-19 patients. *Front Immunol*. 2022: 13.
- Daamen AR, Bachali P, Owen KA, Kingsmore KM., Hubbard EL, Labonte AC, et al. Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. *Sci Rep*. 2021;11(1):7052.
- Dadson P, Tetteh CD, Rebelos E, Badeau RM, Moczulski D. Underlying Kidney Diseases and Complications for COVID-19: A Review. *Front Med*. 2020; 7:600144.
- de Almeida-Pititto B, Dualib PM, Zajdenverg L. et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. *Diabetol Metab Syndr*. 2020; 12:75.
- de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. *Diabet Metabol Syndrome Clin Res Rev*. 2020; (14):597–600.
- Dinas Kesehatan Kota Padang . Situasi Terkini Perkembangan Kasus COVID-19 di Kota Padang. 2021. Available from : https://dinkes.padang.go.id/situasi-terkini-perkembangan-kasus-coronavirus-disease-covid-19-di-kota-padang_07-oktober-2021-update-pukul-300-wib. Diakses pada tanggal 10 Oktober 2021.
- Du P, Geng J, Wang F, Chen X, Huang Z, Wang Y. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. *Int J Med Sci*. 2021; 18(6): 1356–62.
- Ensembl Asia 2021 Gene: IFNG, Ensembl. Available from: http://asia.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000111537;r=12:68154768-68159740;T=Enst00000229135.
- Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. *J Exp Med*. 1987; 166(2):571-6.
- Fariya A, Yusha Araf, Mohammad JH. Corticosteroids for COVID-19: worth it or not?. *Mol Biol Rep*. 2022; 499: 567–76.
- Federico N, Stefanelli, FL, Di Vico V, Cattarin L, Cirella I, Scaparrotta G, et al. The Supporting Role of Combined and Sequential Extracorporeal Blood

- Purification Therapies in COVID-19 Patients in Intensive Care Unit. *Biomedicines*.2022; 10(8).
- Fields JK, Günther S. and Sundberg EJ. Structural Basis of IL-1 Family Cytokine Signaling. *Front Immunol*. 2019; 10 : 1412.
- Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. *J Clin Endocr*. 1999; 84(8):2834–9.
- Fricke-Galindo I and Falfán-Valencia, R. Genetics Insight for COVID-19 Susceptibility and Severity: A Review .*Front Immunol*. 2021; 12:622176.
- Ganesan SK, Venkatratnam P, Mahendra J, Devarajan N. Increased mortality of COVID-19 infected diabetes patients: role of furin proteases. *Int J Obes*.2020; 44(12): 2486–8.
- García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. *Front Immunol*. 2020; 11:1441.
- Genome Locator. Exon Structure for CXCR3. 2020. Available from: https://genecards.weizmann.ac.il/genelocbin/exon_struct.pl?disp_name=CXCR3&chr_nr=X.
- Gorham J, Moreau A, Corazza F, Peluso L, Ponthieux F, et al. Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. *PLOS ONE* .2020; 15(12).
- Gudowska-Sawczuk M, Mroczko, B. What Is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection?. *Int J Mol Sci*. 2022; 23(7): 3673.
- Guirao JJ, Cabrera CM, Jiménez N, Rincón L, & Urra JM. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. *Mol Immunol*. 2020; 128:64–8.
- Guo C, Li B, Ma H. Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. *Nat Commun*. 2020; 11:3924.
- Gupta RK, Nwachuku EL, Zusman BE, Jha RM, & Puccio AM. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. *PloS one*. 2021; 16(9).
- Gustine JN. and Jones D. Immunopathology of Hyperinflammation in COVID-19. *Am J Clin Pathol*. 2021; 191(1):4–17.
- Hawrylowicz C, Richards D, Loke TK, Corrigan, C, & Lee T. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. *J Allergy Clin Immunol*. 2002; 109(2): 369–70.
- Heewon Seo, Yohan Choi, Jangsoo Shim, Youngsok Choi, Hakhyun Ka. Regulatory Mechanism for Expression of IL1B Receptors in the Uterine Endometrium and Effects of IL1B on Prostaglandin Synthetic Enzymes During the Implantation Period in Pigs. *Biol Reprod*. 2012; 87(2):1–11.
- Hikmawati I, Setiyabudi R. Epidemiology of COVID-19 in Indonesia: common source and propagated source as a cause for outbreaks. *J Infect Dev Ctries*. 2021; 15(05):646-652.
- Hirano T. IL-6 in inflammation, autoimmunity and cancer. *Int. Immunol*. 2021; 33(3): 127–48.

- Hu ZJ, Xu J, Yin JM, Li L, Hou W, Zhang, et al. Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients. *Front. Immunol.* 2020; 11.
- Huang TJ, Li YY, Weng YJ, Cheng CC, Hsu RW. Interleukin-6 protein expression is more important than interleukin-6 mRNA levels in assessing surgical invasiveness. *J Surg Res.* 2007; 142(1):53-8.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020; 395(10223): 497–506.
- Hu R, Han C, Pei S, Yin M, & Chen X. Procalcitonin levels in COVID-19 patients. *Int J Antimicrob Agents.* 2020; 56(2):106051.
- IFNG Gene Interferon Gamma, Gene. 2021. Available at: <https://www.genecards.org/cgi-bin/carddisp.pl?gene=IFNG>.
- In Hilbert, Pincket Robbe. Transcripts Per Million Ratio: a novel batch and sample control method over an established paradigm. 2022. Available from: https://www.researchgate.net/publication/360462495_Transcripts_Per_Million_Ratio_a_novel_batch_and_sample_control_method_over_an_established_paradigm.
- Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, & Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. *J Allergy Clin Immunol.* 2002; 109(4):649–57.
- Islam H, Chamberlain TC, Mui AL, Little JP. Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action?. *Front Immunol.* 2021;12:677008.
- Issa R, Xie S, Khorasani N, Sukkar M, Adcock IM, Lee KY, et al. Corticosteroid inhibition of growth-related oncogene protein-alpha via mitogen-activated kinase phosphatase-1 in airway smooth muscle cells. *J Immun J.* 2007; 178(11):7366–75.
- Jang TN, Yeh DY, Shen SH, Huang CH, Jiang JS, and Kao SJ. Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases. *J Infect.* 2004; 48 (1):23–31.
- Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. *medRxiv.* 2020.
- Jose MG, Sebastian CR, Emilia RV, et.al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. *Allergy Asthma Immunol.* 2020; 147 (1)
- Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. *J Community Empowerment Health.* 2020 :77-82
- Kaur S. ‘Genomics’, in Brenner’s Encyclopedia of Genetics. Elsevier. 2013 :310–12.
- Khalil B.A, Elemam NM and Maghazachi, AA. Chemokines and chemokine receptors during COVID-19 infection. *Comput Struct Biotechnol J.* 2021; 19: 976–88.
- Kim PY, Mengyuan Y, Ke Z, Weiling Z, Xiaobo. ExonSkipDB: functional annotation of exon skipping event in human. *Nucleic acids res.* 2019 :48

- Kopitar-Jerala N. The Role of Interferons in Inflammation and Inflammasome Activation. *Front Immunol.* 2017; 8:873.
- Koukkunen, Karri P, Art K, Matti H, Ilkka P, Tapio R, et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor- α in the prognostic classification of unstable angina pectoris. *Ann. Med.* 2001; 33: 37-47.
- Kowalik MM, Trzonkowski P, Łasińska KM, Mital A, Smiatacz T, Jaguszewski M. COVID-19 - Toward a comprehensive understanding of the disease. *Cardiol J.* 2020; 27(2): 99–114.
- Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence. *Cardiovasc Res.* 2020; 116:1688–99.
- Kurniawan E. Info COVID-19 Sumbar pada tanggal Kamis 7 Oktober 2021. 2021. Available at : <https://www.sumbarprov.go.id>. Diakses pada tanggal 9 Oktober 2021.
- Kvastad L, Carlberg K, Larsson . The spatial RNA integrity number assay for in situ evaluation of transcriptome quality. *Commun Biol.* 2021; 4:57
- Langereis JD, Oudijk EJ, Schweizer RC, Lammers JW, Koenderman L, Ulfman LH. Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1 β synthesis by human neutrophils. *Eur Respir J.* 2011; 37(2):406-15.
- LaRossa RA. ‘Transcriptome’, in Brenner’s Encyclopedia of Genetics. Elsevier. 2013 :101–103.
- Lauring AS, & Malani PN . Variants of SARS-CoV-2. *Jama.* 2021; 326(9):880.
- Lee N, Chan KCA, Hui D, Wu A, Chiu R. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *J Clin. Virol.* 2004; 31 (4): 304–9.
- Lev S, Gottesman T, Levin GS, Lederfein D, Berkov E, Diker D. Real-time IP-10 measurements as a new tool for inflammation regulation within a clinical decision support protocol for managing severe COVID-19 patients. *medRxiv.* 2020 :20158782.
- Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chim Acta.* 2020; 505:190–1.
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y. Early Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med.* 2020; 382:1199–207.
- Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.* 2020; 146(1):110–8.
- Lim S, Bae J.H, Kwon HS. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol.* 2021; 17:11–30.
- Lin F, Young H.A. The talented interferon-gamma. *J adv biol biotechnol.* 2013: 6-13.
- Lio D, Scola L, Giarratana RM, Candore G, Colonna-Romano G, Caruso C, et al. SARS CoV2 infection-The longevity study perspectives. *Ageing Res Rev.* 2021; 67:101299.

- Liu ZM, Li JP, Wang SP, Chen D, Zeng W, Chen S, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. *Int J Med. Sci.* 2020; 17:2468–76.
- Lopez-Castejon G and Brough D. Understanding the mechanism of IL-1 β secretion. *Cytokine & Growth Factor Rev.* 2011; 22(4):189–95.
- Lorè NI, De Lorenzo R, Rancoita P, Cugnata F, Agresti A, Benedetti F, et al. CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. *Mol. Med.* 2021; 27(1):129.
- Lu L, Zhang H, Dauphars DJ, & He YW. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. *Trends immunol.* 2021; 42(1):3–5.
- Luo Yand Zheng SG. Hall of Fame among Pro-inflammatory Cytokines: Interleukin-6 Gene and Its Transcriptional Regulation Mechanisms. *Front Immunol.* 2016: 7.
- Ma Y, Zeng H, Zhan Z, Lu H, Zeng Z, He C, et al. Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China. *Front Pharmacol.* 2020; 11:1198.
- Mann EH, Gabryšová L, Pfeffer PE, O'Garra A, & Hawrylowicz CM. High-Dose IL-2 Skews a Glucocorticoid-Driven IL-17⁺IL-10⁺ Memory CD4⁺ T Cell Response towards a Single IL-10-Producing Phenotype. *J immunol.* 2019 :684–93.
- Mathieu B, Jacquier, M., Aho Glele, LS. CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS. *Crit Care.* 2020; 24:632.
- Mattos-Silva P, Nathane SF, Pedro LS. Pros and cons of corticosteroid therapy for COVID-19 patients. *Respir Physiol Neurobiol.* 2020: 280.
- Metcalfe RD, Putoczki TL and Griffin MDW. Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11. *Front Immunol.* 2020;11: 1424.
- Metzemaekers M, Vanheule V, Janssens R, Struyf S, Proost P. Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands. *Front immunol.* 2020; 8: 1970.
- Mirjalili H, Dastgheib SA, Shaker SH, Bahrami R, Mazaheri M, Sadr-Bafghi, et al. Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis. *J. Diabetes Metab. Disord.* 2021; 20(1): 905–17.
- Mubarik S, Liu X, Eshak ES, Liu K, Liu Q, Wang F, et al. The Association of Hypertension With the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan, China: A Multicenter Retrospective Cohort Study. *Front Med.* 2021; 8:623608.
- Muelle O, Lightfoot S, Schroeder, A. RNA Integrity Number (RIN)-Standardization of RNA Quality Control. *Agilent Application Note.* 2022.
- Naik NB, Puri GD, Kajal K, Mahajan V, Bhalla A, Kataria S, et al. High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial. *Cureus.* 2021; 13(12): 20353.
- Naji HS. Cytokine Storm of SARS-CoV-2, the Virus that Causes COVID-19. *Eur J Med Sci.* 2020; 2(3).

- NCBI Homo Sapiens (human) IL1A, IL1B, IL1R1, ILR2, IL6, IL6R, TNFa, CXCL10, CXCR3. 2021. Available at: <https://www.ncbi.nlm.nih.gov/gene>.
- NCBI IFNGR1. 2021. Available at: <https://www.ncbi.nlm.nih.gov/gene/3459>.
- Newton K and Dixit VM. Signaling in Innate Immunity and Inflammation. *Cold Spring Harb Perspect Biol.* 2012; 4(3): 6049.
- Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. *Nature.* 2021; 591(7848): 92–8.
- Paschoud S, Dogar AM, Kuntz C, Grisoni-Neupert B, Richman L, Kühn LC. Destabilization of interleukin-6 mRNA requires a putative RNA stem-loop structure, an AU-rich element, and the RNA-binding protein AUF1. *Mol Cell Biol.* 2006; 26(22):8228-41.
- Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy AG, et al. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. *Eur J Intern Med.* 2021; 86:34-40.
- Phei CL, Kar LW, Retha R. Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis. *J Pharm Sci.* 2021; 30: 211–28
- Pinteaux E, Abdulaal WH, Mufazalov IA. Cell-specific conditional deletion of interleukin-1 (IL-1) ligands and its receptors: a new toolbox to study the role of IL-1 in health and disease. *J Mol Med.* 2020; 98:923–30.
- Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. *Physiol Genom.* 2020; 52:549–57.
- Ponce, Daniela & Zamoner, Welder & Magalhães. Kinetics of Plasma Cytokines During and After Two Different Modalities of Extracorporeal Blood Purification in Critically Ill COVID-19 Patients. *Int J Nephrol Renovasc Dis.* 2020; 15:309-17.
- Pubchem Homo Sapiens (human) IL1A, IL1B, IL1R1, ILR2, IL6, IL6R, TNFa, CXCL10, CXCR3. 2020. Available at: <https://pubchem.ncbi.nlm.nih.gov/gene>.
- Qi S, Ngwa C, Morales Scheihing DA. Sex differences in the immune response to acute COVID-19 respiratory tract infection. *Biol Sex Differ.* 2021: 66
- Rosyanti L. and Hadi I. Respon Imunitas Dan Badai Sitokin Severe Acute Respiratory Syndrome Corona Virus 2 Literatur Review. *Jurnal Madani Medika.* 2020; 11(02):26.
- Samir A, Wagner T, Venkatakrishnan AJ. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. *Cell Death Discov.* 2021; 7:55.
- Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. *Front Immunol.* 2021; 12:613422.
- Saunders H, Sanghavi D. Continuous Renal Replacement Therapy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022
- Savan R, Ravichandran S, Collins JR, Sakai M, Young HA. Structural conservation of interferon gamma among vertebrates. *Cytokine Growth Factor Rev.* 2009; 20(2):115-124.

- Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. *J Leukoc Biol.*2004; 75(2):163-189.
- Schroeder A, Mueller O, Stocker S. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. *BMC Molecular Biol.* 2006; 7: 3
- Sharma JR. and Yadav UCS. COVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical intervention. *Obes Res Clin Pract.* 2021; 15(2): 163–71.
- Sharma A. Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic data. *Gene.* 2021; 788:145665.
- Shaul Lev, Gottesman T, Sahaf Levin G. Observational cohort study of IP-10's potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19. *PloS one*, 2021; 16(1).
- Shen Y, Cheng C, Zheng X, Jin Y, Duan G, Chen M, et al. Elevated Procalcitonin Is Positively Associated with the Severity of COVID-19: A Meta-Analysis Based on 10 Cohort Studies. *Medicina.* 2021; 57:594.
- Sherwani S and Khan MWA. ‘Cytokine Response in SARS-CoV-2 Infection in the Elderly’ *J Inflamm.* 202; 13: 737–47.
- Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J.. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. *Crit Care;* 2020; 24:108.
- Shoab N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, et al. COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. *PLoS One.*2021; 16(8):e0255999.
- Siddiqi HK and Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. *J Heart Lung Transplant.* 2020; 39(5):405–7.
- Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Interleukin-6: structure-function relationships. *Protein Sci.* 1997; 6(5):929-55.
- Smieszek SP, Przychodzen BP, Polymeropoulos VM, Polymeropoulos CM, Polymeropoulos MH. Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients. *Cytokine.* 2021; 148:155662.
- Smit MJ, Verdijk P, van der Raaij-Helmer EM. CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. *Blood.* 2013; 102(6):1959-65.
- Sugiyama M, Kinoshita N, Ide S. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. *Gene.*2021;766:145145.
- Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. *Lancet Reg. Health West. Pac.* 2021; 9:100108.
- Swaroop S, Mahadevan A, Shankar SK. HSP60 critically regulates endogenous IL-1 β production in activated microglia by stimulating NLRP3 inflammasome pathway. *J Neuroinflammation.* 2018; 15: 177.

- Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. *Front Immunol.* 2020; 11:1708.
- Temizoz B, Ishii KJ. Type I and II interferons toward ideal vaccine and immunotherapy. *Expert Rev Vaccines.* 2021; 20(5):527-44.
- Thomas N, Gurvich C, Kulkarni J. Sex Differences and COVID-19. *Adv Exp Med Biol.* 2021; 1327:79-91.
- Timo Q, Ng YC, Ramsay EE, Henness S, Allen JC, Parmentier J, Ge Q, et al. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. *Am J Respir Cell Mol.* 2008; 39(2):208–17.
- Tong-Minh K, van der Does Y, Engelen S. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. *BMC Infect Dis.* 2022; 22:165.
- Vakil MK, Mansoori Y, Al-Awsi G. Individual genetic variability mainly of Proinflammatory cytokines, cytokine receptors, and toll-like receptors dictates pathophysiology of COVID-19 disease. *J med virol.* 2022; 94(9):4088–96.
- Vasilyev F, Silkov A and Sennikov S. Relationship between interleukin-1 type 1 and 2 receptor gene polymorphisms and the expression level of membrane-bound receptors. *Cell Mol Immunol.* 2015; 2(2): 222–30.
- Vazirinejad R, Ahmadi Z, Kazemi Arababadi M, Hassanshahi G, Kennedy D. The Biological Functions, Structure and Sources of CXCL10 and Its Outstanding Part in the Pathophysiology of Multiple Sclerosis. *Neuroimmunomodulation.* 2014; 21:322-30.
- Wang HJ, Ding YQ, Li X, Yang L, Zhang WL, and Kang W. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. *N Engl J Med.* 2003; 349 (5): 507–8.
- Wang Z, Gerstein M and Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet.* 2009; 10(1): 57–63.
- Whittle JS, Pavlov I, Sacchetti AD, Atwood C, & Rosenberg MS. Respiratory support for adult patients with COVID-19. *J Am Coll Emerg Physicians Open.* 2020; 1(2): 95–101.
- World Health Organization. Tatalaksana klinis infeksi saluran pernapasan akut berat (SARI) suspek penyakit COVID-19 (versi 1.2). World Health Organization. 2019.
- Xiaoyu Hu, Wai-Ping Li, Charis Meng and Lionel B. Ivashkiv. Inhibition of IFN- γ Signaling by Glucocorticoids. *J Immunol.* 2003. 170: 4833-39.
- Xu K, Wei Y, Giunta S, Zhou M, Xia S. Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?. *Exp Gerontol.* 2021; 151:111423.
- Yang JW, Yang L, Luo RG, & Xu JF. Corticosteroid administration for viral pneumonia: COVID-19 and beyond. *Clin Microbiol Infect.* 2020; 26(9), :1171–7.
- Yang L, Liu S, Liu J. COVID-19: immunopathogenesis and Immunotherapeutics. *Signal Transduct Target Ther.* 2020; 5(1):128.

- Yang Y, Shen C, Li J. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. *J Allergy Clin Immunol*. 2020; 146(1):119–27.
- Yang L, Xie X, Tu Z. The signal pathways and treatment of cytokine storm in COVID-19. *Sig Transduct Target Ther*. 2021; 6:255.
- Yang X, Rutkovsky AC, Zhou J, Zhong Y, Reese J, Schnell T, et al. Characterization of Altered Gene Expression and Histone Methylation in Peripheral Blood Mononuclear Cells Regulating Inflammation in COVID-19 Patients. *J Immunol*. 2022; 208(8):1968-77.
- Zarębska-Michaluk D, Jaroszewicz J, Rogalska M, Lorenc B, Rorat M, Szymanek-Pasternak, et al. Impact of Kidney Failure on the Severity of COVID-19. *J Clin Med*. 2021; 10(9):2042.
- Zhang, Xuemei Qiu, Yang Liu, Juan Wang, Xipeng Li, Xiuli Wang. Expression analysis of three immune genes interferon gamma, Mx and interferon regulatory factor-1 of Japanese flounder (*paralichthys olivaceus*). *Braz Arch Biol Technol*. 2017: 60.
- Zhang J. Yin and yang interplay of IFN- γ in inflammation and autoimmune disease. *J Clin Investig*. 2007; 117(4): 871–3.
- Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. *J Transl Med T*. 2020; 18(1):406.
- Zhang N, Zhao YD, Wang XM. CXCL10 an important chemokine associated with cytokine storm in COVID-19 infected patients. *Eur Rev Med Pharmacol Sci*. 2020; 24(13):7497-505.
- Zhang Q, Bastard P, Liu Z. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*. 2020.
- Zhang S, Cao J. A close examination of double filtering with fold change and t test in microarray analysis. *BMC Bioinformatics*. 2009; 10:402.
- Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, & Saif LJ. Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome. *J virol*. 2008; 82(9):4420–8.
- Zhao S, Ye Z, Stanton R. Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols. *RNA*. 2020; 26(8):903-9.
- Zhao Y, Li MC, Konaté MM. TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository. *J Transl Med*. 2021; 19(1):269.
- Zheng M, Wang X, Guo H. The Cytokine Profiles and Immune Response Are Increased in COVID-19 Patients with Type 2 Diabetes Mellitus. *J Diabetes Res*. 2021; 2021:9526701.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China. 2019. *N Engl J Med*. 2020; 382(8): 727-33.
- Ziehr DR, Alladina J, Petri CR. Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study. *Am J Respir Crit Care Med*. 2020;201(12):1560-4.